Total Payments
$5,477
2024 Payments
$972.20
Companies
49
Transactions
318
Medicare Patients
11,787
Medicare Billing
$1.2M
Payment Breakdown by Category
Food & Beverage$5,409 (98.8%)
Education$68.18 (1.2%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $5,409 | 313 | 98.8% |
| Education | $68.18 | 5 | 1.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $589.65 | 36 | $0 (2024) |
| Astellas Pharma US Inc | $531.83 | 32 | $0 (2024) |
| ABBVIE INC. | $462.55 | 33 | $0 (2024) |
| PFIZER INC. | $386.89 | 29 | $0 (2024) |
| Janssen Biotech, Inc. | $361.59 | 24 | $0 (2024) |
| Myriad Genetic Laboratories, Inc. | $272.12 | 16 | $0 (2024) |
| Edap Technomed Inc | $258.00 | 3 | $0 (2024) |
| Myovant Sciences Inc. | $176.62 | 8 | $0 (2022) |
| Medtronic USA, Inc. | $165.89 | 5 | $0 (2019) |
| Bayer Healthcare Pharmaceuticals Inc. | $158.60 | 10 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $972.20 | 44 | Edap Technomed Inc ($258.00) |
| 2023 | $901.03 | 51 | Myriad Genetic Laboratories, Inc. ($173.76) |
| 2022 | $804.36 | 48 | ABBVIE INC. ($108.10) |
| 2021 | $682.82 | 40 | Teleflex LLC ($97.65) |
| 2020 | $325.65 | 22 | NeoTract Inc. ($86.14) |
| 2019 | $685.55 | 42 | PFIZER INC. ($118.69) |
| 2018 | $502.09 | 37 | PFIZER INC. ($87.18) |
| 2017 | $603.34 | 34 | Astellas Pharma US Inc ($202.26) |
All Payment Transactions
318 individual payment records from CMS Open Payments — Page 1 of 13
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/16/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $19.70 | General |
| Category: Oncology | ||||||
| 12/10/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $17.93 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 11/07/2024 | Myriad Genetic Laboratories, Inc. | PROLARIS (Device) | Food and Beverage | In-kind items and services | $18.59 | General |
| Category: ONCOLOGY | ||||||
| 10/21/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $18.09 | General |
| Category: Oncology | ||||||
| 10/18/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $23.90 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 10/07/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $10.59 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 09/27/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $16.31 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 09/18/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $16.50 | General |
| Category: ONCOLOGY | ||||||
| 09/17/2024 | IMMUNITYBIO, INC. | ANKTIVA (Drug) | Food and Beverage | In-kind items and services | $16.56 | General |
| Category: Immunotherapy | ||||||
| 09/09/2024 | Novartis Pharmaceuticals Corporation | PLUVICTO (Drug) | Food and Beverage | In-kind items and services | $16.40 | General |
| Category: Oncology | ||||||
| 09/04/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: HORMONE THERAPY | ||||||
| 08/27/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $16.57 | General |
| Category: UROLOGY | ||||||
| 08/20/2024 | UROGEN PHARMA, INC. | JELMYTO (Drug) | Food and Beverage | In-kind items and services | $18.75 | General |
| Category: UROTHELIAL CANCER | ||||||
| 08/16/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $14.06 | General |
| Category: ONCOLOGY | ||||||
| 08/13/2024 | Janssen Biotech, Inc. | ERLEADA (Drug), AKEEGA, BALVERSA | Food and Beverage | In-kind items and services | $17.52 | General |
| Category: Oncology | ||||||
| 08/12/2024 | Edap Technomed Inc | — | Food and Beverage | Cash or cash equivalent | $86.00 | General |
| 08/12/2024 | Edap Technomed Inc | — | Food and Beverage | Cash or cash equivalent | $86.00 | General |
| 08/12/2024 | Edap Technomed Inc | — | Food and Beverage | Cash or cash equivalent | $86.00 | General |
| 07/23/2024 | Dendreon Pharmaceuticals LLC | PROVENGE (Drug) | Food and Beverage | In-kind items and services | $24.85 | General |
| Category: CELLULAR BIOLOGIC TREATMENT FOR PROSTATE CANCER | ||||||
| 07/18/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $16.74 | General |
| Category: ONCOLOGY | ||||||
| 07/15/2024 | C. R. Bard, Inc. & Subsidiaries | Bard Urinary Drainage Bag (Device) | Food and Beverage | In-kind items and services | $15.58 | General |
| Category: Urology | ||||||
| 07/09/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $18.14 | General |
| Category: ONCOLOGY | ||||||
| 06/26/2024 | Telix Pharmaceuticals | ILLUCCIX (Drug), ILLUCCIX | Food and Beverage | In-kind items and services | $18.13 | General |
| Category: PROSTATE CANCER THERAPY | ||||||
| 06/21/2024 | Agiliti Surgical, Inc. | Sonablate HIFU (Device), Dornier Thulio | Food and Beverage | Cash or cash equivalent | $26.15 | General |
| Category: Surgical Lasers | ||||||
| 06/11/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $17.40 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 38 | 3,488 | 5,445 | $2.5M | $347,963 |
| 2022 | 32 | 3,029 | 4,359 | $2.3M | $321,790 |
| 2021 | 36 | 2,768 | 4,243 | $1.2M | $303,602 |
| 2020 | 38 | 2,502 | 3,865 | $945,897 | $247,737 |
Total Patients
11,787
Total Services
17,912
Medicare Billing
$1.2M
Procedure Codes
147
All Medicare Procedures & Services
147 procedure records from CMS Medicare Utilization — Page 2 of 6
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 87500 | Detection test by nucleic acid for vancomycin resistance strep (vre), amplified probe technique | Office | 2023 | 30 | 34 | $3,944 | $1,169 | 29.6% |
| 87529 | Detection test by nucleic acid for herpes simplex virus, amplified probe technique | Office | 2023 | 30 | 34 | $3,944 | $1,169 | 29.6% |
| 87532 | Detection test by nucleic acid for herpes virus-6, amplified probe technique | Office | 2023 | 30 | 34 | $3,944 | $1,169 | 29.6% |
| 87653 | Detection test by nucleic acid for strep (streptococcus, group b), amplified probe technique | Office | 2023 | 30 | 34 | $3,944 | $1,169 | 29.6% |
| 87496 | Detection test by nucleic acid for cytomegalovirus (cmv), amplified probe technique | Office | 2023 | 29 | 33 | $3,828 | $1,135 | 29.6% |
| 87640 | Detection test by nucleic acid for staphylococcus aureus (bacteria), amplified probe technique | Office | 2023 | 29 | 33 | $3,828 | $1,135 | 29.6% |
| 87641 | Detection test by nucleic acid for staphylococcus aureus, methicillin resistant (mrsa bacteria), amplified probe technique | Office | 2023 | 29 | 33 | $3,828 | $1,135 | 29.6% |
| 87651 | Detection test by nucleic acid for strep (streptococcus, group a), amplified probe technique | Office | 2023 | 29 | 33 | $3,828 | $1,135 | 29.6% |
| 51741 | Electronic assessment of bladder emptying | Office | 2023 | 86 | 101 | $7,878 | $1,054 | 13.4% |
| 52005 | Insertion of tube into ureter using an endoscope through bladder area | Facility | 2023 | 12 | 12 | $21,120 | $1,004 | 4.8% |
| 74420 | Imaging of urinary tract following injection of a contrast agent | Facility | 2023 | 37 | 39 | $16,400 | $790.53 | 4.8% |
| 84153 | Psa (prostate specific antigen) measurement, total | Office | 2023 | 30 | 32 | $480.00 | $455.70 | 94.9% |
| 36415 | Insertion of needle into vein for collection of blood sample | Office | 2023 | 33 | 35 | $525.00 | $294.00 | 56.0% |
| 76000 | Imaging guidance for procedure, 60 minutes or less | Facility | 2023 | 18 | 20 | $4,840 | $259.00 | 5.4% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 527 | 849 | $602,790 | $90,138 | 15.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 429 | 544 | $272,544 | $39,590 | 14.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 286 | 473 | $180,686 | $28,843 | 16.0% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 194 | 212 | $153,276 | $24,395 | 15.9% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2022 | 24 | 163 | $115,730 | $22,706 | 19.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 158 | 158 | $144,570 | $21,358 | 14.8% |
| 52356 | Crushing of stone of ureter with insertion of stent using an endoscope | Facility | 2022 | 30 | 34 | $75,582 | $11,705 | 15.5% |
| 50590 | Shock wave crushing of kidney stones | Facility | 2022 | 21 | 22 | $91,388 | $10,928 | 12.0% |
| 52601 | Removal of prostate gland using an electrocautery knife through urethra with control of bleeding using an endoscope | Facility | 2022 | 13 | 13 | $51,220 | $8,192 | 16.0% |
| 99454 | Remote monitoring of physiologic parameters, initial supply of devices with daily recordings or programmed alerts transmission, each 30 days | Office | 2022 | 64 | 167 | $16,700 | $7,633 | 45.7% |
| 99457 | Management using the results of remote vital sign monitoring per calendar month, first 20 minutes | Office | 2022 | 50 | 165 | $14,850 | $6,939 | 46.7% |
About Dr. Mark Perlmutter, M.D
Dr. Mark Perlmutter, M.D is a Urology healthcare provider based in Manasquan, New Jersey. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/26/2007. The National Provider Identifier (NPI) number assigned to this provider is 1154511012.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Perlmutter, M.D has received a total of $5,477 in payments from pharmaceutical and medical device companies, with $972.20 received in 2024. These payments were reported across 318 transactions from 49 companies. The most common payment nature is "Food and Beverage" ($5,409).
As a Medicare-enrolled provider, Perlmutter has provided services to 11,787 Medicare beneficiaries, totaling 17,912 services with total Medicare billing of $1.2M. Data is available for 4 years (2020–2023), covering 147 distinct procedure/service records.
Ad
Practice Information
- Specialty Urology
- Other Specialties Urology
- Location Manasquan, NJ
- Active Since 07/26/2007
- Last Updated 07/10/2010
- Taxonomy Code 208800000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1154511012
Products in Payments
- PROVENGE (Drug) $607.61
- XTANDI (Drug) $439.95
- INTERSTIM (Device) $280.12
- ELIGARD (Drug) $263.69
- ERLEADA (Drug) $255.31
- ORGOVYX (Drug) $221.84
- PROLARIS (Device) $206.49
- Androgel (Drug) $178.85
- Xtandi (Drug) $169.69
- Myrbetriq (Drug) $166.05
- LUPRON DEPOT (Drug) $145.29
- BOTOX (Biological) $137.21
- UroLift (Device) $126.79
- Nubeqa (Drug) $114.99
- UroLift System (Device) $114.66
- JELMYTO (Drug) $109.56
- KEYTRUDA (Biological) $93.54
- Erleada (Drug) $92.95
- FOUNDATIONONE (Device) $81.26
- MYRBETRIQ (Drug) $62.39
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.